Tag: press

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against PetMed Express, Inc. (“PetMed” or the “Company”) (NASDAQ: PETS) on behalf of PetMed stockholders. Our investigation concerns whether PetMed has violated the federal securities laws and/or engaged in other unlawful business practices.

Trading to Commence Under Symbol “BTCT”

Tiburon, CA, June 26, 2025 (GLOBE NEWSWIRE) -- FIGX Capital Acquisition Corp. (the “Company”) announced today the pricing of its initial public offering of 13,100,000 units. The units are expected to be listed on The Nasdaq Global Stock Market LLC (“Nasdaq”) and begin trading tomorrow, June 27, 2025, under the ticker symbol “FIGXU.” Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to certain adjustments. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. An amount equal to $10.00 per unit will be deposited into a trust account upon the closing of the offering. Once the securities constituting the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “FIGX” and “FIGXW,” respectively. The offering is expected to close on June 30, 2025, subject to customary closing conditions. The Company has granted the underwriters a 45-day option to purchase up to an additional 1,965,000 units at the initial public offering price to cover over-allotments, if any.

RACINE, Wis., June 26, 2025 (GLOBE NEWSWIRE) -- Johnson Outdoors Inc. (Nasdaq: JOUT), a leading global innovator of outdoor recreation equipment and technology, today announced approval by its Board of Directors of a quarterly cash dividend of $0.33 per Class A share and $0.30 per Class B share.

SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced the closing of its underwritten public offering of 9,147,727 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,193,181 shares, at a price to the public of $44.00 per share. The gross proceeds to Cidara from the offering, before deducting underwriting discounts and commissions and offering expenses, were $402.5 million. All of the shares in the offering were sold by Cidara.